Final Results from the Phase II Trial of Brentuximab Vedotin in Mycosis Fungoides or Sézary Syndrome


Final Results from the Phase II Trial of Brentuximab Vedotin in Mycosis Fungoides or Sézary Syndrome
Slides from a presentation at ASH 2014 and transcribed comments from a recent interview with Craig Moskowitz, MD (1/6/15)
Kim YH et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides or Sezary syndrome: Final results show significant clinical activity and suggest correlation with CD30 expression. Proc ASH 2014;Abstract 804.

Dr Moskowitz is Clinical Director of the Division of Hematologic Oncology, Attending Physician in Lymphoma and Adult BMT Services, Member of Memorial Sloan Kettering Cancer Center and Professor of Medicine at Weill Medical College of Cornell University in New York, New York.